Redeye maintains its valuation and positive view of Enea, following our estimate changes yesterday. Shares still trade at a meager 13X EV/EBIT 21E. We raise our sight, beyond the Corona crisis, and expect the Stratum deal of USD 15-20m to drive solid growth from 2021.